Sartorius Stedim Biotech (SSB) and Repligen have entered into a collaboration agreement to introduce next-generation perfusion-enabled bioreactors.
Mergers
Through this partnership, the companies will combine Repligen’s XCell ATF cell retention control technology into SSB’s BIOSTAT STR large-scale single-use bioreactors to create novel perfusion-enabled bioreactors. Therefore, the end user should benefit from a single-control system for 50–2,000 L bioreactors used in perfusion cell culture applications.
Additionally, the companies will further collaborate to equip SSB’s ambr 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo hollow fibre filter technology, to be sold by SSB as a complete single-use assembly.
“Sartorius Stedim Biotech has continuously expanded its integrated upstream portfolio over the past years with a focus on robust and scalable, automated single-use solutions, optimised for high-cell-density applications,” commented Stefan Schlack, head of marketing at SSB. “The collaboration with Repligen will result in easy-to-implement, high-performance and perfusion-ready bioreactors ranging from process development to commercial manufacturing scale.”
“We are excited to partner with Sartorius Stedim Biotech, a global innovator in bioreactor technology,” stated Christine Gebski, vice president of Product Management at Repligen. “The integration of our market-leading XCell ATF control technology with SSB’s high-performance bioreactors offers a simplified perfusion-enabled bioreactor solution for end users to develop cell culture processes more quickly and implement perfusion more efficiently.”